Supriya Lifescience Limited disclosed on April 7, 2026, that its promoters and members of the promoter group have not encumbered any shares directly or indirectly during the financial year ended March 31, 2026. This declaration, submitted to the Bombay Stock Exchange and the National Stock Exchange, confirms that the shareholding of the promoter group remains free of any charges or liens, ensuring stability in the ownership structure.

The disclosure was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The regulation requires promoters to inform the exchanges if they have pledged their shares as collateral or created any other encumbrance during a financial year. The absence of such encumbrance indicates that the promoters have not utilized their shareholding for raising external funds during the specified period.

The filing was made on behalf of the promoter, Satish Waman Wagh, and the members of the promoter group. The list of individuals and entities comprising the promoter group includes family members and various private limited companies associated with the promoters.

The following table details the names of the promoters and members of the promoter group as disclosed in the filing:

The document was digitally signed by Satish Waman Wagh on April 7, 2026. A copy of the disclosure was also forwarded to the Audit Committee of Supriya Lifescience Limited for its records.

Supriya Lifescience Ltd has detailed the tax deduction provisions for the final dividend of Re 1.00 per share recommended for the financial year 2025-26. The Board of Directors approved the recommendation at its meeting held on May 27, 2026. The dividend payout, representing 50% of the face value of Rs 2 per equity share, is taxable in the hands of shareholders under the Income Tax Act, 2025. The company will deduct tax at source (TDS) at the time of payment, with rates varying based on the residential status and category of the shareholder.

Tax Deduction for Resident Shareholders

For resident shareholders, TDS will be deducted at 10% on the dividend amount under Section 393(1) and Section 393(4) of the Act. However, no TDS will apply to resident individuals if the aggregate dividend paid during the tax year 2026-27 does not exceed Rs 10,000. Shareholders with valid Permanent Account Numbers (PAN) linked to Aadhaar will be subject to the standard rate, while those with inoperative PAN or missing PAN will face higher tax rates. Exemptions are available for specific entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIF) upon submission of valid self-declaration forms.

Provisions for Non-Resident Shareholders

Non-resident shareholders, including Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs), are subject to a withholding tax of 20% plus applicable surcharge and cess. These shareholders may opt for benefits under the Double Taxation Avoidance Agreement (DTAA) if more favorable. To avail DTAA benefits, non-resident shareholders must submit a self-attested copy of their PAN, a valid Tax Residency Certificate (TRC) for TY 2026-27, and E-Form 41 filed on the income tax portal. The company reserves the right to apply DTAA rates at its sole discretion following a satisfactory review of the submitted documents.

Compliance and Documentation Requirements

Shareholders must ensure their details, including PAN, residential status, and bank account information, are updated with their depository participants or the company's Registrar & Share Transfer Agent, MUFG Intime India Private Limited. Documents claiming exemption or lower tax rates must be submitted to the RTA on or before July 15, 2026. The company will not accept any communication regarding tax determination after this date. Shareholders are advised that any excess tax deducted due to missing or defective documentation can be claimed as a refund by filing an income tax return.